HK1119672A1 - Biphenyl compounds useful in the synthesis of muscarinic receptor antagonists - Google Patents

Biphenyl compounds useful in the synthesis of muscarinic receptor antagonists

Info

Publication number
HK1119672A1
HK1119672A1 HK08111328.2A HK08111328A HK1119672A1 HK 1119672 A1 HK1119672 A1 HK 1119672A1 HK 08111328 A HK08111328 A HK 08111328A HK 1119672 A1 HK1119672 A1 HK 1119672A1
Authority
HK
Hong Kong
Prior art keywords
synthesis
receptor antagonists
compounds useful
muscarinic receptor
biphenyl compounds
Prior art date
Application number
HK08111328.2A
Other languages
English (en)
Inventor
Mathai Mammen
Yu-Hua Ji
Yongqi Mu
Craig Husfeld
Li Li
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of HK1119672A1 publication Critical patent/HK1119672A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK08111328.2A 2004-03-11 2008-10-14 Biphenyl compounds useful in the synthesis of muscarinic receptor antagonists HK1119672A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55244304P 2004-03-11 2004-03-11

Publications (1)

Publication Number Publication Date
HK1119672A1 true HK1119672A1 (en) 2009-03-13

Family

ID=34963910

Family Applications (2)

Application Number Title Priority Date Filing Date
HK07103327A HK1097537A1 (en) 2004-03-11 2007-03-28 Biphenyl compounds useful as muscarinic receptor antagonists
HK08111328.2A HK1119672A1 (en) 2004-03-11 2008-10-14 Biphenyl compounds useful in the synthesis of muscarinic receptor antagonists

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK07103327A HK1097537A1 (en) 2004-03-11 2007-03-28 Biphenyl compounds useful as muscarinic receptor antagonists

Country Status (28)

Country Link
US (22) US7288657B2 (xx)
EP (2) EP1930323B1 (xx)
JP (1) JP4837653B2 (xx)
KR (1) KR101174740B1 (xx)
CN (1) CN1930125B (xx)
AR (2) AR048032A1 (xx)
AT (2) ATE467617T1 (xx)
AU (1) AU2005222411B2 (xx)
BR (1) BRPI0508622B8 (xx)
CA (1) CA2557479C (xx)
CY (1) CY1109015T1 (xx)
DE (2) DE602005006757D1 (xx)
DK (1) DK1723114T3 (xx)
ES (2) ES2306125T3 (xx)
HK (2) HK1097537A1 (xx)
HR (1) HRP20080301T3 (xx)
IL (1) IL177359A (xx)
MA (1) MA28524B1 (xx)
MY (1) MY144482A (xx)
NO (1) NO338941B1 (xx)
NZ (1) NZ549472A (xx)
PL (1) PL1723114T3 (xx)
PT (1) PT1723114E (xx)
RU (1) RU2366656C2 (xx)
SI (1) SI1723114T1 (xx)
TW (1) TWI341836B (xx)
WO (1) WO2005087738A1 (xx)
ZA (1) ZA200607099B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087733A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528413A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
US7262205B2 (en) * 2004-03-11 2007-08-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7456199B2 (en) * 2004-03-11 2008-11-25 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200538095A (en) * 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1723115A1 (en) * 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
EP1856112A1 (en) * 2005-03-10 2007-11-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200714587A (en) * 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7659403B2 (en) * 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2006099031A1 (en) * 2005-03-10 2006-09-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI372749B (en) 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
EP1866284A1 (en) * 2005-03-10 2007-12-19 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2006138218A1 (en) * 2005-06-13 2006-12-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
DK3210981T3 (en) 2009-04-23 2019-04-01 Theravance Respiratory Co Llc DIAMIDE COMPOUNDS WITH MUSCARINE RECEPTOR ANTAGONIST AND BETA-2 ADDRESSER RECEPTOR AGONIST ACTIVITY
PT2453894E (pt) 2009-07-15 2016-02-02 Theravance Biopharma R&D Ip Llc Forma de base livre cristalina de um composto bifenilo
WO2012009166A1 (en) * 2010-07-13 2012-01-19 Theravance, Inc. Process for preparing a biphenyl-2-ylcarbamic acid
US10092552B2 (en) * 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9679336B2 (en) * 2011-10-19 2017-06-13 Facebook, Inc. Social ad hoc networking protocol and presentation layer
WO2016155573A1 (zh) * 2015-03-27 2016-10-06 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
CN107849047B (zh) * 2015-09-28 2021-01-15 四川海思科制药有限公司 一种联苯衍生物及其制备方法和在医药上的用途
CN107849009B (zh) * 2015-10-13 2021-03-02 四川海思科制药有限公司 一种八氢环戊二烯并[c]吡咯衍生物及其制备方法和在医药上的用途
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
WO2020181035A1 (en) * 2019-03-06 2020-09-10 Barry university Muscarinic agonists as non-steroidal and non-opioid analgesics and methods of use thereof
CN110526859B (zh) * 2019-08-07 2021-03-12 山东百诺医药股份有限公司 一种瑞维那新中间体及其制备方法和瑞维那新的制备方法
CN112694434B (zh) * 2020-12-29 2023-06-16 浙江和泽医药科技股份有限公司 一种雷芬那辛新中间体及其活性亲电砌块和雷芬那辛的新制备方法
WO2023017404A1 (en) * 2021-08-13 2023-02-16 Begum Dr M Sasthaa A device, a compound, for inhalation of an anti-viral agent
CN118401497A (zh) 2021-12-09 2024-07-26 医药化学公司 雷芬那辛的结晶型丙酮溶剂化物
CN117263848A (zh) * 2023-09-19 2023-12-22 山东京卫制药有限公司 一种雷芬那辛的吸入喷雾剂

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US747952A (en) * 1903-03-02 1903-12-29 Harry Cauley Dillon Ironing-board.
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
GR861995B (en) 1985-07-30 1986-11-04 Glaxo Group Ltd Devices for administering medicaments to patients
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
WO1992022286A1 (en) 1991-06-12 1992-12-23 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
US5337740A (en) 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
DE69218455T2 (de) 1991-12-18 1997-10-23 Minnesota Mining And Mfg. Co., Saint Paul, Minn. Aerosolzusammensetzungen für arzneimittelsuspensionen
WO1993011773A1 (en) 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
GB9206989D0 (en) 1992-03-31 1992-05-13 Glaxo Group Ltd Chemical compounds
US5239993A (en) 1992-08-26 1993-08-31 Glaxo Inc. Dosage inhalator providing optimized compound inhalation trajectory
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
US5415162A (en) 1994-01-18 1995-05-16 Glaxo Inc. Multi-dose dry powder inhalation device
KR970701174A (ko) 1994-02-10 1997-03-17 오노다 마사요시 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same)
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
RU2126001C1 (ru) * 1995-01-10 1999-02-10 Самдзин Фармасьютикал Ко., Лтд Производные пиперазина и фармацевтическая композиция на их основе
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
EP0820323B1 (en) 1995-04-14 2003-09-24 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
US6464979B1 (en) * 1996-09-12 2002-10-15 Aventis Pasteur Limited Chlamydial vaccines and methods of preparation thereof
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
WO1999016766A1 (fr) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Derives de benzodioxole
ES2224628T3 (es) 1998-03-14 2005-03-01 Altana Pharma Ag Inhibidores de pde iii/iv a base de ftalazinonas.
MA26621A1 (fr) 1998-04-18 2004-12-20 Glaxo Group Ltd Composition pour aerosols pharmaceutiques
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
JP2002517464A (ja) 1998-06-08 2002-06-18 アドバンスド メディスン インコーポレーテッド ムスカリン性レセプターアンタゴニスト
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
ATE233084T1 (de) 1999-04-14 2003-03-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung
DE19933926A1 (de) 1999-07-20 2001-01-25 Boehringer Ingelheim Pharma Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
US6510182B1 (en) * 1999-10-25 2003-01-21 Freesystems Pte. Ltd. Wireless infrared digital audio system
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
US7238709B2 (en) * 1999-12-07 2007-07-03 Theravance, Inc. Therapeutic carbamates
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
DK1345937T3 (da) 2000-12-22 2006-01-16 Almirall Prodesfarma Ag Quinuclidincarbamatderivater og deres anvendelse som M3-antagonister
US6656694B2 (en) 2001-01-11 2003-12-02 Theravance, Inc. Method for identifying a ligand for a biological substrate
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ　グループ　リミテッド βアドレナリン受容体のアゴニスト
ES2296923T3 (es) 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
USRE44874E1 (en) 2001-09-14 2014-04-29 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
AU2003258507A1 (en) 2002-07-30 2004-02-23 Unilever Plc Abrasive hard surface cleaning compositions
AR040779A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CA2543858C (en) 2003-11-21 2014-04-15 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7456199B2 (en) * 2004-03-11 2008-11-25 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200538095A (en) * 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087733A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1723115A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528413A (ja) 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
JP2007528415A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
US7262205B2 (en) 2004-03-11 2007-08-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2006099031A1 (en) 2005-03-10 2006-09-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200714587A (en) 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1856112A1 (en) * 2005-03-10 2007-11-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7659403B2 (en) 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1866284A1 (en) 2005-03-10 2007-12-19 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI372749B (en) 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
WO2006138218A1 (en) 2005-06-13 2006-12-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US20070029346A1 (en) * 2005-08-03 2007-02-08 Fu-Tian Hung Pneumatic greaser
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
CA2861601A1 (en) * 2006-04-27 2007-11-08 Intezyne Technologies, Inc. Poly (ethylene glycol) containing chemically disparate endgroups
PT2453894E (pt) 2009-07-15 2016-02-02 Theravance Biopharma R&D Ip Llc Forma de base livre cristalina de um composto bifenilo
WO2012009166A1 (en) 2010-07-13 2012-01-19 Theravance, Inc. Process for preparing a biphenyl-2-ylcarbamic acid

Also Published As

Publication number Publication date
US8017783B2 (en) 2011-09-13
PL1723114T3 (pl) 2008-10-31
DE602005006757D1 (de) 2008-06-26
CN1930125A (zh) 2007-03-14
US7910608B2 (en) 2011-03-22
US20180179161A1 (en) 2018-06-28
US20190359570A1 (en) 2019-11-28
CY1109015T1 (el) 2014-07-02
ATE395335T1 (de) 2008-05-15
AR104444A2 (es) 2017-07-19
MA28524B1 (fr) 2007-04-03
IL177359A0 (en) 2006-12-10
US20100249421A1 (en) 2010-09-30
US7288657B2 (en) 2007-10-30
EP1723114A1 (en) 2006-11-22
US20050203133A1 (en) 2005-09-15
TWI341836B (en) 2011-05-11
US20140171397A1 (en) 2014-06-19
US9283183B2 (en) 2016-03-15
US9926272B2 (en) 2018-03-27
US7521041B2 (en) 2009-04-21
US7803812B2 (en) 2010-09-28
US20160220551A1 (en) 2016-08-04
SI1723114T1 (sl) 2008-08-31
US20190047957A1 (en) 2019-02-14
US20070292357A1 (en) 2007-12-20
CN1930125B (zh) 2010-07-21
US20150164795A1 (en) 2015-06-18
US11247969B2 (en) 2022-02-15
US10106503B2 (en) 2018-10-23
WO2005087738A1 (en) 2005-09-22
US20110319625A1 (en) 2011-12-29
CA2557479C (en) 2013-05-07
NZ549472A (en) 2010-06-25
US20090018165A1 (en) 2009-01-15
ATE467617T1 (de) 2010-05-15
NO20064579L (no) 2006-11-08
US7585879B2 (en) 2009-09-08
US20090226379A1 (en) 2009-09-10
ZA200607099B (en) 2008-09-25
ES2306125T3 (es) 2008-11-01
US20170204061A1 (en) 2017-07-20
EP1930323A1 (en) 2008-06-11
BRPI0508622B1 (pt) 2018-05-22
EP1723114B1 (en) 2008-05-14
IL177359A (en) 2012-04-30
US7550595B2 (en) 2009-06-23
BRPI0508622A (pt) 2007-07-31
US8053448B2 (en) 2011-11-08
JP4837653B2 (ja) 2011-12-14
JP2008532922A (ja) 2008-08-21
US9452161B2 (en) 2016-09-27
KR20070011370A (ko) 2007-01-24
US20130172301A1 (en) 2013-07-04
KR101174740B1 (ko) 2012-08-17
RU2006135927A (ru) 2008-04-20
AU2005222411A1 (en) 2005-09-22
HK1097537A1 (en) 2007-06-29
US8034946B2 (en) 2011-10-11
US8912334B2 (en) 2014-12-16
US8173815B2 (en) 2012-05-08
AR048032A1 (es) 2006-03-22
US20080071088A1 (en) 2008-03-20
US20080095708A1 (en) 2008-04-24
US20220306579A1 (en) 2022-09-29
TW200538438A (en) 2005-12-01
DE602005021258D1 (de) 2010-06-24
US20070265305A1 (en) 2007-11-15
US8273894B2 (en) 2012-09-25
AU2005222411B2 (en) 2011-04-21
MY144482A (en) 2011-09-30
US10343995B2 (en) 2019-07-09
US20110130422A1 (en) 2011-06-02
CA2557479A1 (en) 2005-09-22
HRP20080301T3 (en) 2008-09-30
US20070292356A1 (en) 2007-12-20
US20120190657A1 (en) 2012-07-26
EP1930323B1 (en) 2010-05-12
PT1723114E (pt) 2008-07-17
DK1723114T3 (da) 2008-07-28
BRPI0508622B8 (pt) 2021-05-25
ES2345640T3 (es) 2010-09-28
US8557997B2 (en) 2013-10-15
US10570092B2 (en) 2020-02-25
NO338941B1 (no) 2016-10-31
RU2366656C2 (ru) 2009-09-10
US7491736B2 (en) 2009-02-17
US20200290966A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
HK1119672A1 (en) Biphenyl compounds useful in the synthesis of muscarinic receptor antagonists
HUS1400053I1 (hu) Muszkarin acetilkolin receptor antagonisták
IL177057A0 (en) Triazole compounds and their use as metabotropic glutamate receptor antagonists
IL176775A0 (en) Muscarinic acetylcholine receptor antagonists
EP1725236A4 (en) NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
EP1957075A4 (en) NOVEL ANTAGONISTS OF ACETYLCHOLINE M3 TYPE MUSCARINIC RECEPTORS
EP1937068A4 (en) ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
EP1824483A4 (en) ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
EP1749012A4 (en) ANTAGONISTS OF MUSCARIN ACETYLCHOLIN RECEPTOR
EP1827439A4 (en) NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
EP1725240A4 (en) ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
IL179462A0 (en) Use of the receptor gpr86
EP1725238A4 (en) ACETYLCHOLINE M 3 MUSCARINIC RECEPTOR ANTAGONISTS
IL190686A0 (en) Il-21 receptor antagonists
IL174846A0 (en) Muscarinic acetylcholine receptor antagonists
EP1747219A4 (en) Antagonists of muscarinic acetylcholine receptor
EP1765339A4 (en) ANTAGONISTS OF MUSCARIN ACETYLCHOLIN RECEPTOR
EP1937230A4 (en) M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
EP1937267A4 (en) M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
EP1781104A4 (en) ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
EP1648462A4 (en) ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
EP1648461A4 (en) MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
EP1781103A4 (en) ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
EP1751089A4 (en) NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
EP1725241A4 (en) ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC M3 RECEPTOR